{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:46:03Z","timestamp":1782715563047,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 109-2320-B-039-055"],"award-info":[{"award-number":["MOST 109-2320-B-039-055"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012544","name":"China Medical University, Taiwan","doi-asserted-by":"publisher","award":["CMU112-S-12"],"award-info":[{"award-number":["CMU112-S-12"]}],"id":[{"id":"10.13039\/501100012544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11064-026-04800-z","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:46:58Z","timestamp":1780894018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["8-Gingerol Mitigates MPP+-Induced \u03b1-Synuclein Aggregation and NLRP3 Inflammasome Activation by Inducing the Insulin Signaling Pathway in SH-SY5Y Cells"],"prefix":"10.1007","volume":"51","author":[{"given":"Ya-Chen","family":"Shih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Yu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Huei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jung","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Wen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"5","key":"4800_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"GBDN Collaborators","year":"2019","unstructured":"Collaborators GBDN (2019) Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(5):459\u2013480","journal-title":"Lancet Neurol"},{"issue":"9","key":"4800_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.tins.2013.06.003","volume":"36","author":"L Brichta","year":"2013","unstructured":"Brichta L, Greengard P, Flajolet M (2013) Advances in the pharmacological treatment of Parkinson\u2019s disease: targeting neurotransmitter systems. Trends Neurosci 36(9):543\u2013554","journal-title":"Trends Neurosci"},{"key":"4800_CR3","volume-title":"Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogenesis","author":"A Kouli","year":"2018","unstructured":"Kouli A, Torsney KM, Kuan WL (2018) In: Stoker TB, Greenland JC (eds) Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogenesis. Pathogenesis and Clinical Aspects, Parkinson\u2019s Disease"},{"issue":"10423","key":"4800_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH (2024) The pathogenesis of Parkinson\u2019s disease. Lancet 403(10423):293\u2013304","journal-title":"Lancet"},{"issue":"8","key":"4800_CR5","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00702-010-0431-6","volume":"117","author":"KA Maguire-Zeiss","year":"2010","unstructured":"Maguire-Zeiss KA, Federoff HJ (2010) Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson\u2019s disease. J Neural Transm (Vienna) 117(8):1019\u20131025","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"4800_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/mds.27874","volume":"35","author":"ME Haque","year":"2020","unstructured":"Haque ME, Akther M, Jakaria M, Kim IS, Azam S, Choi DK (2020) Targeting the microglial NLRP3 inflammasome and its role in Parkinson\u2019s disease. Mov Disord 35(1):20\u201333","journal-title":"Mov Disord"},{"issue":"2","key":"4800_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41418-018-0124-5","volume":"26","author":"E Lee","year":"2019","unstructured":"Lee E, Hwang I, Park S, Hong S, Hwang B, Cho Y, Son J, Yu JW (2019) MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ 26(2):213\u2013228","journal-title":"Cell Death Differ"},{"issue":"2","key":"4800_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0301-0082(01)00003-X","volume":"65","author":"D Blum","year":"2001","unstructured":"Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson\u2019s disease. Prog Neurobiol 65(2):135\u2013172","journal-title":"Prog Neurobiol"},{"issue":"9","key":"4800_CR9","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/j.freeradbiomed.2012.08.569","volume":"53","author":"R Perfeito","year":"2012","unstructured":"Perfeito R, Cunha-Oliveira T, Rego AC (2012) Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease\u2013resemblance to the effect of amphetamine drugs of abuse. Free Radic Biol Med 53(9):1791\u20131806","journal-title":"Free Radic Biol Med"},{"issue":"7","key":"4800_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm.3893","volume":"21","author":"H Guo","year":"2015","unstructured":"Guo H, Callaway JB, Ting JPY (2015) Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 21(7):677\u2013687","journal-title":"Nat Med"},{"key":"4800_CR11","doi-asserted-by":"publisher","first-page":"102299","DOI":"10.1016\/j.jaut.2019.06.010","volume":"103","author":"JI Shin","year":"2019","unstructured":"Shin JI, Lee KH, Joo YH, Lee JM, Jeon J, Jung HJ, Shin M, Cho S, Kim TH, Park S, Jeon BY, Jeong H, Lee K, Kang K, Oh M, Lee H, Lee S, Kwon Y, Oh GH, Kronbichler A (2019) Inflammasomes and autoimmune and rheumatic diseases: A comprehensive review. J Autoimmun 103:102299","journal-title":"J Autoimmun"},{"issue":"2","key":"4800_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10(2):417\u2013426","journal-title":"Mol Cell"},{"issue":"1\u20134","key":"4800_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3109\/00207459309003322","volume":"69","author":"R Sandyk","year":"1993","unstructured":"Sandyk R (1993) The relationship between diabetes mellitus and Parkinson\u2019s disease. Int J Neurosci 69(1\u20134):125\u2013130","journal-title":"Int J Neurosci"},{"issue":"4","key":"4800_CR14","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2337\/dc10-1922","volume":"34","author":"Q Xu","year":"2011","unstructured":"Xu Q, Park Y, Huang X, Hollenbeck A, Blair A, Schatzkin A, Chen H (2011) Diabetes and risk of Parkinson\u2019s disease. Diabetes Care 34(4):910\u2013915","journal-title":"Diabetes Care"},{"key":"4800_CR15","doi-asserted-by":"publisher","first-page":"1356703","DOI":"10.3389\/fnins.2024.1356703","volume":"18","author":"M Ay","year":"2024","unstructured":"Ay M, Charli A, Langley M, Jang A, Padhi P, Jin H, Anantharam V, Kalyanaraman B, Kanthasamy A, Kanthasamy AG (2024) Mito-metformin protects against mitochondrial dysfunction and dopaminergic neuronal degeneration by activating upstream PKD1 signaling in cell culture and MitoPark animal models of Parkinson\u2019s disease. Front Neurosci 18:1356703","journal-title":"Front Neurosci"},{"key":"4800_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.neuropharm.2018.02.012","volume":"133","author":"P Feng","year":"2018","unstructured":"Feng P, Zhang X, Li D, Ji C, Yuan Z, Wang R, Xue G, Li G, H\u00f6lscher C (2018) Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson\u2019s disease. Neuropharmacology 133:385\u2013394","journal-title":"Neuropharmacology"},{"key":"4800_CR17","doi-asserted-by":"crossref","unstructured":"Athauda D, Foltynie T (2016) Insulin resistance and Parkinson\u2019s disease: A new target for disease modification? Prog Neurobiol, 145\u2013146, 98\u2013120","DOI":"10.1016\/j.pneurobio.2016.10.001"},{"key":"4800_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.nbd.2014.03.011","volume":"67","author":"SE Arnold","year":"2014","unstructured":"Arnold SE, Lucki I, Brookshire BR, Carlson GC, Browne CA, Kazi H, Bang S, Choi BR, Chen Y, McMullen MF, Kim SF (2014) High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice. Neurobiol Dis 67:79\u201387","journal-title":"Neurobiol Dis"},{"issue":"4","key":"4800_CR19","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/gutjnl-2017-315123","volume":"68","author":"MJ Heo","year":"2019","unstructured":"Heo MJ, Kim TH, You JS, Blaya D, Sancho-Bru P, Kim SG (2019) Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression. Gut 68(4):708\u2013720","journal-title":"Gut"},{"key":"4800_CR20","doi-asserted-by":"crossref","unstructured":"Mohd Sahardi NFN, Makpol S (2019) Ginger (Zingiber officinale Roscoe) in the Prevention of Ageing and Degenerative Diseases: Review of Current Evidence. Evid Based Complement Alternat Med, 2019, 5054395","DOI":"10.1155\/2019\/5054395"},{"issue":"3","key":"4800_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.phanu.2016.02.004","volume":"4","author":"JL Funk","year":"2016","unstructured":"Funk JL, Frye JB, Oyarzo JN, Chen J, Zhang H, Timmermann BN (2016) Anti-Inflammatory Effects of the Essential Oils of Ginger (Zingiber officinale Roscoe) in Experimental Rheumatoid Arthritis. PharmaNutrition 4(3):123\u2013131","journal-title":"PharmaNutrition"},{"issue":"3","key":"4800_CR22","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.3390\/molecules16032636","volume":"16","author":"J Lu","year":"2011","unstructured":"Lu J, Guan S, Shen X, Qian W, Huang G, Deng X, Xie G (2011) Immunosuppressive activity of 8-gingerol on immune responses in mice. Molecules 16(3):2636\u20132645","journal-title":"Molecules"},{"issue":"9","key":"4800_CR23","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/ptr.5871","volume":"31","author":"F Zhang","year":"2017","unstructured":"Zhang F, Ma N, Gao YF, Sun LL, Zhang JG (2017) Therapeutic Effects of 6-Gingerol, 8-Gingerol, and 10-Gingerol on Dextran Sulfate Sodium-Induced Acute Ulcerative Colitis in Rats. Phytother Res 31(9):1427\u20131432","journal-title":"Phytother Res"},{"issue":"1","key":"4800_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctim.2013.12.017","volume":"22","author":"H Mozaffari-Khosravi","year":"2014","unstructured":"Mozaffari-Khosravi H, Talaei B, Jalali BA, Najarzadeh A, Mozayan MR (2014) The effect of ginger powder supplementation on insulin resistance and glycemic indices in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Complement Ther Med 22(1):9\u201316","journal-title":"Complement Ther Med"},{"key":"4800_CR25","doi-asserted-by":"publisher","first-page":"156580","DOI":"10.1016\/j.phymed.2025.156580","volume":"140","author":"X Tang","year":"2025","unstructured":"Tang X, Huang L, Ma W, Huang M, Zeng Z, Yu Y, Qin N, Zhou F, Li F, Gong S (2025) Intestinal 8 gingerol attenuates TBI-induced neuroinflammation by inhibiting microglia NLRP3 inflammasome activation in a PINK1\/Parkin-dependent manner. Phytomedicine 140:156580","journal-title":"Phytomedicine"},{"key":"4800_CR26","doi-asserted-by":"publisher","first-page":"912609","DOI":"10.3389\/fphar.2022.912609","volume":"13","author":"C-L Shen","year":"2022","unstructured":"Shen C-L, Wang R, Yakhnitsa V, Santos JM, Watson C, Kiritoshi T, Ji G, Hamood AN, Neugebauer V (2022) Gingerol-enriched ginger supplementation mitigates neuropathic pain via mitigating intestinal permeability and neuroinflammation: gut-brain connection. Front Pharmacol 13:912609","journal-title":"Front Pharmacol"},{"key":"4800_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fnins.2018.00073","volume":"12","author":"L Yang","year":"2018","unstructured":"Yang L, Wang H, Liu L, Xie A (2018) The Role of Insulin\/IGF-1\/PI3K\/Akt\/GSK3beta Signaling in Parkinson\u2019s Disease Dementia. Front Neurosci 12:73","journal-title":"Front Neurosci"},{"issue":"1","key":"4800_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00726-001-0111-9","volume":"23","author":"O Hornykiewicz","year":"2002","unstructured":"Hornykiewicz O (2002) From a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 23(1):65\u201370","journal-title":"Amino Acids"},{"key":"4800_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2016.07.019","volume":"32","author":"D Athauda","year":"2016","unstructured":"Athauda D, Foltynie T (2016a) Challenges in detecting disease modification in Parkinson\u2019s disease clinical trials. Parkinsonism Relat Disord 32:1\u201311","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"4800_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-1-14","volume":"1","author":"WJ Streit","year":"2004","unstructured":"Streit WJ, Mrak RE, Griffin WST (2004) Microglia and neuroinflammation: a pathological perspective. J Neuroinflamm 1(1):14","journal-title":"J Neuroinflamm"},{"issue":"6","key":"4800_CR31","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/mds.28551","volume":"36","author":"H Chohan","year":"2021","unstructured":"Chohan H, Senkevich K, Patel RK, Bestwick JP, Jacobs BM, Ciga B, Gan-Or S, Z., Noyce AJ (2021) Type 2 diabetes as a determinant of Parkinson\u2019s disease risk and progression. Mov Disord 36(6):1420\u20131429","journal-title":"Mov Disord"},{"key":"4800_CR32","doi-asserted-by":"crossref","unstructured":"Bassil F, Delamarre A, Canron MH, Dutheil N, Vital A, N\u00e9grier-Leibreich ML, Bezard E, Fernagut PO, Meissner WG (2022) Impaired brain insulin signalling in Parkinson\u2019s disease. Neuropathol Appl Neurobiol, 48(1), e12760","DOI":"10.1111\/nan.12760"},{"key":"4800_CR33","doi-asserted-by":"crossref","unstructured":"Lv M, Xue G, Cheng H, Meng P, Lian X, H\u00f6lscher C, Li D (2021) The GLP-1\/GIP dual\u2010receptor agonist DA5\u2010CH inhibits the NF\u2010\u03baB inflammatory pathway in the MPTP mouse model of Parkinson\u2019s disease more effectively than the GLP\u20101 single\u2010receptor agonist NLY01. Brain Behav, 11(8), e2231","DOI":"10.1002\/brb3.2231"},{"issue":"1","key":"4800_CR34","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41420-023-01734-1","volume":"9","author":"J Arcos","year":"2023","unstructured":"Arcos J, Grunenwald F, Sepulveda D, Jerez C, Urbina V, Huerta T, Troncoso-Escudero P, Tirado D, Perez A, Diaz-Espinoza R, Nova E, Kubitscheck U, Rodriguez-Gatica JE, Hetz C, Toledo J, Ahumada P, Rojas-Rivera D, Mart\u00edn-Monta\u00f1ez E, Garcia-Fernandez M, Vidal RL (2023) IGF2 prevents dopaminergic neuronal loss and decreases intracellular alpha-synuclein accumulation in Parkinson\u2019s disease models. Cell Death Discovery 9(1):438","journal-title":"Cell Death Discovery"},{"key":"4800_CR35","doi-asserted-by":"crossref","unstructured":"Bin MBSNA, Razu BA, Hossain MT, Mahzabeen S, Unnoor N, Muna IA, Akhter F, Kabir AU, Hannan J (2017) [6]-Gingerol, from Zingiber officinale, potentiates GLP-1 mediated glucose-stimulated insulin secretion pathway in pancreatic Beta-cells and increases RAB8\/RAB10-regulated membrane presentation of GLUT4 transporters in skeletal muscle to improve hyperglycemia in Leprdb\/db type 2 diabetic mice. BMC Complementary Medicine and Therapies, p 17","DOI":"10.1186\/s12906-017-1903-0"},{"issue":"6","key":"4800_CR36","first-page":"1642","volume":"47","author":"Q-C Zhan","year":"2022","unstructured":"Zhan Q-C, Liu Y-Z, Xi Y-M, Zeng Y, Tian J-Y, Liu L, Li D, Johji Y, Wang J-W (2022) 6-Gingerol ameliorates adipose tissue insulin resistance in aging rats. Zhongguo Zhong yao za zhi= Zhongguo Zhongyao Zazhi=. China J Chin Materia Med 47(6):1642\u20131649","journal-title":"China J Chin Materia Med"},{"issue":"7","key":"4800_CR37","doi-asserted-by":"publisher","first-page":"8166","DOI":"10.1007\/s12035-024-04484-y","volume":"62","author":"S Priyadarshini","year":"2025","unstructured":"Priyadarshini S, Goyal K, Gupta RR, Roy S, Biswas A, Patra R, Chauhan S, Wadhwa P, Singh K, Kamal G, Iqbal M, Alsaweed D, Nuli M, Abomughaid MV, Almutary MM, Sinha AG, Bansal JK, Rani P, Jha B, N. K (2025) Polypharmacology and Neuroprotective Effects of Gingerol in Alzheimer\u2019s Disease. Mol Neurobiol 62(7):8166\u20138186","journal-title":"Mol Neurobiol"},{"issue":"8","key":"4800_CR38","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1158\/1055-9965.EPI-07-2934","volume":"17","author":"SM Zick","year":"2008","unstructured":"Zick SM et al (2008) Pharmacokinetics of 6-Gingerol, 8-Gingerol, 10-Gingerol, and 6-Shogaol and Conjugate Metabolites in Healthy Human Subjects. Cancer Epidemiol Biomarkers Prev 17(8):1930\u20131936","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"4800_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1124\/pharmrev.120.000133","volume":"74","author":"H Grosso Jasutkar","year":"2022","unstructured":"Grosso Jasutkar H, Oh SE, Mouradian MM (2022) Therapeutics in the Pipeline Targeting \u03b1-Synuclein for Parkinson\u2019s Disease. Pharmacol Rev 74(1):207\u2013237","journal-title":"Pharmacol Rev"},{"key":"4800_CR40","doi-asserted-by":"crossref","unstructured":"Zhang X et al (2018) Tau Pathology in Parkinson\u2019s Disease. Frontiers in Neurology, (9), 2018","DOI":"10.3389\/fneur.2018.00809"},{"key":"4800_CR41","doi-asserted-by":"publisher","first-page":"e16635","DOI":"10.7717\/peerj.16635","volume":"11","author":"S Lai","year":"2023","unstructured":"Lai S, Wang P, Gong J, Zhang S (2023) New insights into the role of GSK-3\u03b2 in the brain: from neurodegenerative disease to tumorigenesis. PeerJ 11:e16635","journal-title":"PeerJ"},{"issue":"4","key":"4800_CR42","doi-asserted-by":"publisher","first-page":"417","DOI":"10.4062\/biomolther.2023.098","volume":"31","author":"E Huh","year":"2023","unstructured":"Huh E, Choi JG, Choi Y, Ju IG, Noh D, Shin DY, Kim DH, Park HJ, Oh MS (2023) 6-Shogaol, an Active Ingredient of Ginger, Improves Intestinal and Brain Abnormalities in Proteus Mirabilis-Induced Parkinson\u2019s Disease Mouse Model. Biomol Ther (Seoul) 31(4):417\u2013424","journal-title":"Biomol Ther (Seoul)"},{"issue":"10","key":"4800_CR43","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1021\/acsptsci.2c00104","volume":"5","author":"E Angelopoulou","year":"2022","unstructured":"Angelopoulou E, Paudel YN, Papageorgiou SG, Piperi C (2022) Elucidating the Beneficial Effects of Ginger (Zingiber officinale Roscoe) in Parkinson\u2019s Disease. ACS Pharmacol Transl Sci 5(10):838\u2013848","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"35","key":"4800_CR44","doi-asserted-by":"publisher","first-page":"13106","DOI":"10.1074\/jbc.RA119.008649","volume":"294","author":"M Saline","year":"2019","unstructured":"Saline M, Badertscher L, Wolter M, Lau R, Gunnarsson A, Jacso T, Norris T, Ottmann C, Snijder A (2019) AMPK and AKT protein kinases hierarchically phosphorylate the N-terminus of the FOXO1 transcription factor, modulating interactions with 14-3-3 proteins. J Biol Chem 294(35):13106\u201313116","journal-title":"J Biol Chem"},{"key":"4800_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neulet.2018.06.052","volume":"684","author":"Y Miki","year":"2018","unstructured":"Miki Y, Tanji K, Mori F, Utsumi J, Sasaki H, Kakita A, Takahashi H, Wakabayashi K (2018) Autophagy mediators (FOXO1, SESN3 and TSC2) in Lewy body disease and aging. Neurosci Lett 684:35\u201341","journal-title":"Neurosci Lett"},{"issue":"7","key":"4800_CR46","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.3233\/JPD-223290","volume":"12","author":"LTN Nguyen","year":"2022","unstructured":"Nguyen LTN, Nguyen HD, Kim YJ, Nguyen TT, Lai TT, Lee YK, Ma H-i, Kim YE (2022) Role of NLRP3 inflammasome in Parkinson\u2019s disease and therapeutic considerations. J Parkinson\u2019s Disease 12(7):2117\u20132133","journal-title":"J Parkinson\u2019s Disease"},{"key":"4800_CR47","doi-asserted-by":"crossref","unstructured":"Ho SC, Chang YH (2018) Comparison of Inhibitory Capacities of 6-, 8- and 10-Gingerols\/Shogaols on the Canonical NLRP3 Inflammasome-Mediated IL-1\u03b2 Secretion. Molecules, 23(2)","DOI":"10.3390\/molecules23020466"},{"issue":"16","key":"4800_CR48","doi-asserted-by":"publisher","first-page":"1437138","DOI":"10.3389\/fnagi.2024.1437138","volume":"1","author":"T-H Lin","year":"2024","unstructured":"Lin T-H et al (2024) Coumarin-chalcone derivatives as dual NLRP1 and NLRP3 inflammasome inhibitors targeting oxidative stress and inflammation in neurotoxin-induced HMC3 and BE(2)-M17 cell models of Parkinson\u2019s disease. Front Aging Neurosci 1(16):1437138","journal-title":"Front Aging Neurosci"},{"key":"4800_CR49","doi-asserted-by":"publisher","first-page":"156580","DOI":"10.1016\/j.phymed.2025.156580","volume":"140","author":"X Tang","year":"2025","unstructured":"Tang X et al (2025) Intestinal 8 gingerol attenuates TBI-induced neuroinflammation by inhibiting microglia NLRP3 inflammasome activation in a PINK1\/Parkin-dependent manner. Phytomedicine 140:156580","journal-title":"Phytomedicine"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-026-04800-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-026-04800-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-026-04800-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:04:04Z","timestamp":1782713044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-026-04800-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4800"],"URL":"https:\/\/doi.org\/10.1007\/s11064-026-04800-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8729284\/v1","asserted-by":"object"}]},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"188"}}